“
In the next 5 years , we expect one AMR asset to have completed the pivotal registration trials and be in market
Market size for your products in India and globally ? Revenue expectations in the future ?
Based on the huge unmet market need for a novel broad-spectrum antibiotic that can treat a variety of drug-resistant bacterial infections , we believe BWC0977 has the potential for $ 1billion / year peak sales across indications spanning critical care , public health and biothreat space ( it will take 5years post-launch of drug to hit peak sales of $ 1B ). We believe our best-in-class adenosine antagonists have the potential to capture a market size of $ 3- 5billion / year across a variety of hard-to-treat cancers .
How has the company utilized the $ 18 million funding raised in Series B last year ? Do you plan to go for more funding rounds from VCs in the near future ?
Given the complexity of late-stage clinical development , the funding has supported development of BWC0977 into an intravenous / oral product and progress into Phase 1 studies , expansion of IO portfolio to interrogate multiple targets in modulating the tumour microenvironment . We have built the
PICASO platform – a state-ofthe-art translational laboratory inside a cancer hospital to evaluate effectiveness of our IO molecules to prevent proliferation / reduce primary human tumour volumes . Given our ambitious growth trajectory , we plan to raise more funds in the coming years to support the planned activities towards product registration .
Where do you see the company in the next five years ?
In the next 5 years , we expect one AMR asset to have completed the pivotal registration trials and be in market and two IO assets to have completed Phase 1b trials and ready for outlicensing . We also expect that one or more countries would ’ ve chosen our AMR asset as a biodefense solution to be prepared against potential bioterror warfare .
Key trends in biological therapeutics globally ? Are the Indian companies innovating enough for the future and why ?
The current global innovation wave in basic biology and healthcare is built around advances in omics , molecular technologies and its interplay with bioengineering , high-end computing , machine learning and artificial intelligence . These impactful innovations are enhancing the speed of discovery , scalability and productivity in R & D . A wave of nextgeneration cell and gene therapies are transformative in offering potential cure for certain hard-to-treat diseases . Given our IT
BioTech
BIOVOICENEWS . COM 29